S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.13%) $0.928
USD/NOK
(0.10%) $10.85
USD/GBP
(-0.04%) $0.792
USD/RUB
(-0.07%) $92.51

Realtime updates for ImmunityBio, Inc. [IBRX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
50.00%
return -0.42%
SELL
60.00%
return -8.82%
Last Updated28 Mar 2024 @ 16:00

-1.65% $ 5.37

BUY 62767 min ago

@ $4.52

Issued: 14 Feb 2024 @ 13:58


Return: 18.94%


Previous signal: Feb 14 - 09:30


Previous signal: Sell


Return: 4.24 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems...

Stats
Today's Volume 4.62M
Average Volume 4.02M
Market Cap 3.62B
EPS $-0.350 ( 2024-03-20 )
Next earnings date ( $-0.160 ) 2024-05-09
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -4.67
ATR14 $0.0110 (0.21%)
Insider Trading
Date Person Action Amount type
2024-02-22 Simon Barry J. Buy 159 146 Stock Option (right to buy)
2024-02-22 Simon Barry J. Buy 45 731 Restricted Stock Units
2024-02-22 Lauer Regan J Buy 42 439 Stock Option (right to buy)
2024-02-22 Lauer Regan J Buy 12 195 Restricted Stock Units
2024-02-22 Sachs David C. Buy 424 390 Stock Option (right to buy)
INSIDER POWER
99.25
Last 97 transactions
Buy: 228 380 025 | Sell: 921 083

Volume Correlation

Long: -0.27 (neutral)
Short: -0.89 (strong negative)
Signal:(24.092) Be Aware. Possible trading coming up! (swing)

ImmunityBio, Inc. Correlation

10 Most Positive Correlations
SIRI0.928
RGF0.928
FGBI0.925
AROW0.921
ALRS0.92
GNTY0.92
CBNK0.915
GSMG0.914
GOOD0.906
ALLK0.906
10 Most Negative Correlations
RIVE-0.933
DSEY-0.93
DUOL-0.927
AMPH-0.926
RAM-0.919
INTA-0.919
PLYA-0.918
ALTR-0.91
DAIO-0.909
MLTX-0.907

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ImmunityBio, Inc. Correlation - Currency/Commodity

The country flag -0.36
( neutral )
The country flag 0.38
( neutral )
The country flag 0.00
( neutral )
The country flag 0.58
( weak )
The country flag 0.00
( neutral )
The country flag 0.22
( neutral )

ImmunityBio, Inc. Financials

Annual 2023
Revenue: $622 000
Gross Profit: $-17.89M (-2 876.21 %)
EPS: $-1.150
Q4 2023
Revenue: $139 000
Gross Profit: $-4.43M (-3 183.45 %)
EPS: $-0.350
Q3 2023
Revenue: $82 000.00
Gross Profit: $-4.50M (-5 491.46 %)
EPS: $-0.190
Q2 2023
Revenue: $41 000.00
Gross Profit: $-6.28M (-15 309.76 %)
EPS: $-0.320

Financial Reports:

No articles found.

ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators